课题基金 / 基金详情

CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE

CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE
偶然的无效性和偶然的耐受性
批准号:
3845322
负责人:
S R WEISS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

S R WEISS的其他基金

相似基金

相关文献

中文摘要
翻译
本课题的总体目标是研究现象学。 以及或有药物效应的生物底物。用火柴点燃 范例,我们已经证明了抗惊厥的功效 卡马西平和其他药物可能会受到时间因素的影响 关于药物管理和癫痫发作的陈述。意义重大 到目前为止,调查结果包括以下演示:1)或有 无效,由此卡马西平在 杏仁核点燃癫痫的发展(即,在之前,但不是在之后 电刺激),但不影响点燃发展, 对卡马西平的抗惊厥剂产生了随后的耐受性 对完全点燃的癫痫发作的影响(本应如此 有效);2)或有耐受性,即动物已经完成 反复点燃发作后对卡马西平产生耐受性 在每次电击前而不是在电击后给药 刺激;3)通过以下治疗逆转或有耐受性 卡马西平在点燃发作或单独点燃发作后(无 药物),但不是在一段时间内(没有药物或点燃刺激) 最多三周;4)丙戊酸盐或有不耐药,其中 因丙戊酸盐的偶然性呈现而点燃的动物 在每次刺激(这减缓了点燃的发展)之前, 丙戊酸盐无反应;与非或有暴露于 丙戊酸盐仍然对其抗癫痫作用敏感;5)交叉 丙戊酸盐耐药大鼠对卡马西平的耐受性; 丙戊酸盐点燃动物后这种效应的可逆性 6)卡马西平与卡马西平交叉耐受性 以及与外周型苯二氮卓类受体结合的配体,以及 丙戊酸,但不在卡马西平和安定之间;7)变化 在癫痫阈值中反映了反应性的变化 卡马西平;8)减缓偶发耐受性的发展 非或有药物给药或低剂量点燃大鼠 刺激电流,但不是通过更高剂量的卡马西平; 不同水平点燃对点燃发作阈值的调制作用 刺激;10)NMDA拮抗剂MK-801或钙离子不起作用 通道拮抗剂尼莫地平对偶发耐受发展的影响。
英文摘要
The overall objectives of this project are to the study the phenomenology and biological substrates of contingent drug effects. Using a kindling paradigm, we have demonstrated that the anticonvulsant efficacy of carbamazepine, and other drugs, could be manipulated by temporal factors relating to drug administration and seizure presentation. Significant findings to date include demonstration of the following: 1) contingent inefficacy, whereby the contingent presentation of carbamazepine during amygdala kindling seizure development (i.e., before, but not after electrical stimulation), while not affecting kindling development, produced a subsequent refractoriness to carbamazepine's anticonvulsant effects on completed kindled seizures (when it should have been effective); 2) contingent tolerance, in which animals that have completed kindled seizures develop tolerance to carbamazepine following repeated administration of the drug prior to, but not after, each electrical stimulation; 3) contingent tolerance reversal by treatment with carbamazepine after the kindled seizures or kindled seizures alone (no drug), but not by time off (no drug or kindling stimulation) for periods of up to three weeks; 4) contingent refractoriness to valproate, in which animals that were kindled with the contingent presentation of valproate before each stimulation (which slowed kindling development), became valproate non-responsive; those kindled with non-contingent exposure to valproate remained sensitive to its anticonvulsant effects; 5) cross tolerance to carbamazepine in valproate-refractory rats; and reversibility of this effect by kindling the animals with valproate after each stimulation for one week; 6) cross tolerance between carbamazepine and a ligand that binds the peripheral-type benzodiazepine receptor, and valproic acid, but not between carbamazepine and diazepam; 7) alterations in seizure threshold which mirror the changes in responsivity to carbamazepine; 8) slowing of contingent tolerance development by non-contingent drug presentation or by kindling the rats at lower stimulation currents, but not by higher doses of carbamazepine; 9) modulation of kindled seizure thresholds by different levels of kindling stimulation; 10) no effect of the NMDA antagonist MK-801 or the calcium channel antagonist nimodipine on contingent tolerance development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE
BEHAVIORAL SENSITIZATION
PHARMACOLOGICAL KINDLING
PHARMACOLOGICAL KINDLING
海外基金